Brain secondaries from many primary cancer is always difficult to treat.
Particularly brain secondaries from Lung cancer patients can be quite difficult to treat.
Whole Brain Radiotherpy was widely used in past to treat brain secondaries in Lung cancer patients until 2016.
In 2016, QUARTZ study reported that Radiotherapy provided“ little additional clinically significant benefit for this patient group”.
So very few treatment options existed for this group of patients.
So it’s reassuring to see that a new drug was found to be highly active in lung cancer patients with brain secondaries.
Data presented at ESMO ( European Society of Medical Oncology) shows that the Lorlatinib showed a staggering 82% response rate in a small sub-group of patients.
References 1. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30825-X/fulltext
Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only and do check the the sources where cited. Please consult your own doctor to discuss concerns and options relevant to you.
The views expressed in this blog represent the author’s views held at the time of drafting the blog and is likely to change overtime, particularly when new evidence comes to light. The blog is not necessarily endorsed by any organisation the author is associated with and views are not substitute for professional advice.